Beneficial effects of PPAR-? ligands in ischemia?reperfusion injury, inflammation and shock, Cardiovascular Research, vol.65, issue.4, pp.772-781, 2005. ,
DOI : 10.1016/j.cardiores.2004.12.008
Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17, Journal of Biological Chemistry, vol.66, issue.3, pp.1910-1914, 2003. ,
DOI : 10.4049/jimmunol.167.12.6957
PPAR?? signaling and metabolism: the good, the bad and the future, Nature Medicine, vol.40, issue.5, pp.557-566, 2013. ,
DOI : 10.1093/nar/gks595
PPAR ?? insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors, Journal of Clinical Investigation, vol.113, issue.6, pp.846-855, 2004. ,
DOI : 10.1172/JCI200419900
URL : http://europepmc.org/articles/pmc362117?pdf=render
Interleukin-6: From identification of the cytokine to development of targeted treatments, Joint Bone Spine, vol.77, issue.6, pp.532-536, 2010. ,
DOI : 10.1016/j.jbspin.2010.07.007
PPAR? mutations, lipodystrophy and diabetes. Hormone molecular biology and clinical investigation, pp.63-70, 2014. ,
DOI : 10.1515/hmbci-2014-0033
Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients, Diabetes, vol.46, issue.8, pp.461319-1327, 1997. ,
DOI : 10.2337/diabetes.46.8.1319
PPAR?? Is Required for Placental, Cardiac, and Adipose Tissue Development, Molecular Cell, vol.4, issue.4, pp.585-595, 1999. ,
DOI : 10.1016/S1097-2765(00)80209-9
Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. The journal of Immunology, pp.4008-4016, 2001. ,
Systemic mastocytosis and bone involvement in a cohort of 75 patients, Annals of the Rheumatic Diseases, vol.69, issue.10, pp.1838-1841, 2010. ,
DOI : 10.1136/ard.2009.124511
URL : https://hal.archives-ouvertes.fr/hal-00528144
The mechanisms of action of PPARs. The mechanisms of action of PPARs, pp.409-435, 2002. ,
Th17: the third member of the effector T cell trilogy, Current Opinion in Immunology, vol.19, issue.6, pp.652-657, 2007. ,
DOI : 10.1016/j.coi.2007.07.020
Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. The American journal of pathology, pp.1426-1434, 2009. ,
Mast Cell Hyperplasia: Role of Cytokines, International Archives of Allergy and Immunology, vol.127, issue.2, pp.118-122, 2002. ,
DOI : 10.1159/000048181
Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation, Prostaglandins & Other Lipid Mediators, vol.71, issue.1-2, pp.1-22, 2003. ,
DOI : 10.1016/S0090-6980(03)00003-0
Cell and cytokine imbalances in rheumatoid synovitis, Joint Bone Spine, vol.78, issue.3, pp.230-234, 2011. ,
DOI : 10.1016/j.jbspin.2010.08.017
Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes, The Journal of biological chemistry, issue.16, pp.27512243-12250, 2000. ,
Recent advances in the genetics of RA susceptibility, Rheumatology, vol.47, issue.4, pp.399-402, 2008. ,
DOI : 10.1093/rheumatology/ken005
, but not troglitazone, modulates IL-1?? effects in human chondrocytes by inhibiting NF-??B and AP-1 activation pathways, FEBS Letters, vol.43, issue.1, pp.24-30, 2001. ,
DOI : 10.1021/jm990554g
Functions of RANKL/RANK/OPG in bone modeling and remodeling, Archives of Biochemistry and Biophysics, vol.473, issue.2, pp.139-146, 2008. ,
DOI : 10.1016/j.abb.2008.03.018
The RANKL/RANK/OPG pathway, Current Osteoporosis Reports, vol.83, issue.suppl1, pp.98-104, 2007. ,
DOI : 10.1007/s11914-007-0024-y
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat., Endocrinology, vol.137, issue.1, pp.354-366, 1996. ,
DOI : 10.1210/endo.137.1.8536636
-tryptase, Histamine and Eosinophil Cationic Protein in Synovial Fluid, Clinical Science, vol.93, issue.4, pp.363-370, 1979. ,
DOI : 10.1042/cs0930363
Emerging cell and cytokine targets in rheumatoid arthritis, Nature Reviews Rheumatology, vol.71, issue.2, pp.77-88, 2013. ,
DOI : 10.1038/nrneph.2012.141
Histamine Polarizes Human Dendritic Cells into Th2 Cell-Promoting Effector Dendritic Cells, The Journal of Immunology, vol.167, issue.7, pp.3682-3686, 2001. ,
DOI : 10.4049/jimmunol.167.7.3682
Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation, The Journal of Cell Biology, vol.68, issue.5, pp.851-864, 2015. ,
DOI : 10.1083/jcb.201412074.dv
Fenofibrate, a PPAR?? agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy, American Journal of Physiology-Endocrinology and Metabolism, vol.272, issue.5, pp.790-799, 2011. ,
DOI : 10.1016/S0014-5793(00)01570-2
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies, Rheumatology, vol.156, p.269, 2015. ,
DOI : 10.1007/s00296-010-1429-y
Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines, The journal of Immunology, vol.161, issue.1, pp.409-414, 1998. ,
PPAR-?? dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation, Nature Medicine, vol.274, issue.1, pp.48-52, 2001. ,
DOI : 10.1074/jbc.274.27.19055
Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation, Seminars in Immunology, vol.19, issue.6, pp.400-408, 2007. ,
DOI : 10.1016/j.smim.2007.10.015
The Role of Mast Cells in Osteoporosis, Seminars in Arthritis and Rheumatism, vol.36, issue.1, pp.32-36, 2006. ,
DOI : 10.1016/j.semarthrit.2006.03.004
Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? Arthritis research & therapy, p.246, 2009. ,
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.39, issue.3, pp.614-624, 2002. ,
DOI : 10.1002/art.1780390704
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer, Clinical Pharmacology & Therapeutics, vol.1, issue.4, pp.352-359, 2013. ,
DOI : 10.1016/j.cmet.2012.07.013
Identification of a novel mitochondrial protein (???mitoNEET???) cross-linked specifically by a thiazolidinedione photoprobe, American Journal of Physiology-Endocrinology and Metabolism, vol.286, issue.2, pp.252-60, 2004. ,
DOI : 10.1210/endo.139.12.6364
PPAR? Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us? PPAR research, pp.519724-519733, 2013. ,
Wnt Pathway and IL-17: Novel Regulators of Joint Remodeling in Rheumatic Diseases. Looking Beyond the RANK-RANKL-OPG Axis, Seminars in Arthritis and Rheumatism, vol.39, issue.5, 2008. ,
DOI : 10.1016/j.semarthrit.2008.10.008
Bone Loss in Rheumatoid Arthritis: Systemic, Periarticular, and Focal, Current Rheumatology Reports, vol.13, issue.3, pp.231-237, 2012. ,
DOI : 10.1038/nm1538
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism, Endocrine Reviews, vol.20, issue.5, pp.649-688, 1999. ,
DOI : 10.1210/er.20.5.649
RANK is essential for osteoclast and lymph node development. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, pp.132412-2424, 1999. ,
Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function, European Journal of Immunology, vol.203, issue.7, pp.1883-1893, 2011. ,
DOI : 10.1084/jem.20052288
Peroxisome proliferator-activated receptors: insight into multiple cellular functions, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.448, issue.2, pp.121-138, 2000. ,
DOI : 10.1016/S0027-5107(99)00231-6
Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity, The Egyptian Rheumatologist, vol.37, issue.1, pp.1-6, 2015. ,
DOI : 10.1016/j.ejr.2014.06.001
Peroxisome proliferator-activated receptor ? activators inhibit interleukin-1?-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes, Arthritis & Rheumatism, vol.5, issue.3, pp.595-607, 2001. ,
DOI : 10.1038/372798a0
The role of mast cells in host defense and their subversion by bacterial pathogens, Trends in Immunology, vol.23, issue.3, pp.151-158, 2002. ,
DOI : 10.1016/S1471-4906(01)02156-1
Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss, Proceedings of the National Academy of Sciences, vol.65, issue.4, pp.6027-6032, 2003. ,
DOI : 10.1007/s002239900697
Interleukin-6 as a key player in systemic inflammation and joint destruction, Autoimmunity Reviews, vol.8, issue.7, pp.538-542, 2009. ,
DOI : 10.1016/j.autrev.2009.01.012
Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element, The Journal of biological chemistry, issue.27, pp.27928411-28418, 2004. ,
Peroxisome proliferator-activated receptor-alpha (PPAR??): At the crossroads of obesity, diabetes and cardiovascular disease, Atherosclerosis, vol.205, issue.1, pp.1-8, 2009. ,
DOI : 10.1016/j.atherosclerosis.2009.03.008
IgE and mast cells in allergic disease, Nature Medicine, vol.20, issue.5, pp.693-704, 2012. ,
DOI : 10.1016/S0167-5699(99)01535-2
Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils, Nature Immunology, vol.162, issue.11, pp.1035-1044, 2011. ,
DOI : 10.4161/epi.6.3.14017
Regulatory T Cells Enhance Mast Cell Production of IL-6 via Surface-Bound TGF-??, The Journal of Immunology, vol.188, issue.2, pp.594-603, 1950. ,
DOI : 10.4049/jimmunol.1102389
Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation, Journal of immunology, issue.11, pp.1836903-6912, 1950. ,
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer, Cellular and Molecular Life Sciences, vol.55, issue.7, pp.6-7932, 1999. ,
DOI : 10.1007/s000180050345
Peroxisome proliferator-activated receptor-?? (PPAR-??) ligands as potential therapeutic agents to treat arthritis, Pharmacological Research, vol.60, issue.3, pp.160-169, 2009. ,
DOI : 10.1016/j.phrs.2009.02.005
Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells, Mol Pharmacol, vol.50, issue.5, pp.1087-1094, 1996. ,
Combinatorial roles of nuclear receptors in inflammation and immunity, Nature Reviews Immunology, vol.19, issue.1, pp.44-55, 2006. ,
DOI : 10.1210/me.2004-0529
Pathogenesis of bone and cartilage destruction in rheumatoid arthritis, Rheumatology, vol.42, issue.90002, pp.11-17, 2003. ,
DOI : 10.1093/rheumatology/keg327
Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression, Arthritis & Rheumatism, vol.154, issue.3, pp.479-489, 1997. ,
DOI : 10.1177/37.4.2647838
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor, Arthritis & Rheumatism, vol.43, issue.2, pp.250-258, 2000. ,
DOI : 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P
Skeletal consequences of thiazolidinedione therapy, Osteoporosis International, vol.9, issue.Suppl 1, pp.129-137, 2008. ,
DOI : 10.4158/EP.9.6.544
Prevalence of rheumatoid arthritis in France: 2001, Annals of the Rheumatic Diseases, vol.64, issue.10, pp.1427-1430, 2001. ,
DOI : 10.1136/ard.2004.029199
The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis, European Journal of Immunology, vol.7, issue.4, pp.1098-1105, 2001. ,
DOI : 10.1080/09629359891216
Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights, International Reviews of Immunology, vol.65, issue.1, pp.265-279, 2015. ,
DOI : 10.1016/j.biologicals.2010.07.002
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls, Rheumatology, vol.42, issue.1, pp.123-134, 2003. ,
DOI : 10.1093/rheumatology/keg047
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis, Arthritis & Rheumatism, vol.44, issue.Suppl 6, pp.2327-2337, 2004. ,
DOI : 10.1007/s002960000080
Management of osteoporosis in rheumatoid arthritis patients, Expert Opinion on Pharmacotherapy, vol.45, issue.6, pp.559-571, 2015. ,
DOI : 10.1093/rheumatology/ket468
The rheumatoid arthritis HLA???DRB1 shared epitope, Current Opinion in Rheumatology, vol.22, issue.3, pp.293-298, 2010. ,
DOI : 10.1097/BOR.0b013e328336ba63
Cutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium, The Journal of Immunology, vol.184, issue.7, pp.3336-3340, 1950. ,
DOI : 10.4049/jimmunol.0903566
Adopted orphans as regulators of inflammation, immunity and skeletal homeostasis, Swiss Medical Weekly, vol.144, p.14055, 2014. ,
DOI : 10.4414/smw.2014.14055
Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. The journal of histochemistry and cytochemistry : official journal of the, Histochemistry Society, issue.10, pp.371509-1515, 1989. ,
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature, vol.347, issue.6294, pp.645-650, 1990. ,
DOI : 10.1038/347645a0
Origin, maturation and recruitment of mast cell precursors, Frontiers in bioscience, vol.3, pp.1390-1406, 2011. ,
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature, issue.6662, pp.39182-86, 1998. ,
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores, Arthritis & Rheumatism, vol.43, issue.5, pp.1001-1009, 2000. ,
DOI : 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation, Journal of immunology, issue.9, pp.1635049-5055, 1950. ,
Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body, Blood, vol.103, issue.3, pp.860-867, 2004. ,
DOI : 10.1182/blood-2003-04-1160
Interleukin-17 enhances tumor necrosis factor ?-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: A possible role as a ?fine-tuning cytokine? in inflammation processes, Arthritis & Rheumatism, vol.164, issue.9, pp.2176-2184, 2001. ,
DOI : 10.4049/jimmunol.164.9.4783
ACR/EULAR 2010 rheumatoid arthritis classification criteria, Rheumatology, vol.62, issue.9, pp.5-9, 2012. ,
DOI : 10.1002/art.27580
URL : https://academic.oup.com/rheumatology/article-pdf/51/suppl_6/vi5/5056206/kes279.pdf
Roles of PPARs in health and disease, Nature, vol.402, issue.6785, pp.421-424, 2000. ,
DOI : 10.2337/diabetes.48.7.1466
Peroxisome Proliferator-activated Receptor-??/?? Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity, Journal of Biological Chemistry, vol.280, issue.10, pp.9519-9527, 2005. ,
DOI : 10.1074/jbc.M413808200
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, Archives of Pharmacal Research, vol.371, issue.Suppl 10, pp.575-584, 2015. ,
DOI : 10.1016/S0140-6736(08)60454-7
Immunological reaction in TNF-?-mediated osteoclast formation and bone resorption in vitro and in vivo, Clinical and Developmental Immunology, issue.2, pp.2013181849-2013181857, 2013. ,
The nuclear receptor PPAR?? selectively inhibits Th17 differentiation in a T cell???intrinsic fashion and suppresses CNS autoimmunity, The Journal of Experimental Medicine, vol.524, issue.10, pp.2079-2089, 2009. ,
DOI : 10.1038/nature06878
URL : https://hal.archives-ouvertes.fr/pasteur-00509630
sIL-6R: more than an agonist? Immunology and cell biology, pp.87-91, 2008. ,
Genetic basis of rheumatoid arthritis: a current review. Biochemical and biophysical research communications, pp.254-262, 2014. ,
Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1??, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis, Arthritis & Rheumatism, vol.58, issue.Suppl I, pp.632329-2339, 2011. ,
DOI : 10.1136/ard.58.2008.i40
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis, Nature Medicine, vol.20, issue.1, pp.62-68, 2014. ,
DOI : 10.1016/S1534-5807(02)00369-6
Anakinra for cryopyrin-associated periodic syndrome. Expert review of clinical immunology, pp.7-18, 2014. ,
Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines, Annals of the Rheumatic Diseases, vol.61, issue.8, pp.61704-713, 2002. ,
DOI : 10.1136/ard.61.8.704
An overview on biological mechanisms of PPARs, Pharmacological Research, vol.51, issue.2, pp.85-94, 2005. ,
DOI : 10.1016/j.phrs.2004.07.012
Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients, Arthritis & Rheumatism, vol.247, issue.5, pp.1003-1012, 2001. ,
DOI : 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#
Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis, Arthritis Research & Therapy, vol.10, issue.1, p.6, 2008. ,
DOI : 10.1186/ar2354
URL : https://hal.archives-ouvertes.fr/hal-01715309
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, The Journal of Experimental Medicine, vol.71, issue.2, pp.233-240, 2005. ,
DOI : 10.1038/nri802
Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone, Endocrinology, vol.148, issue.6, pp.2669-2680, 2007. ,
DOI : 10.1210/en.2006-1587
IL-17 produced by neutrophils regulates IFN-?????mediated neutrophil migration in mouse kidney ischemia-reperfusion injury, Journal of Clinical Investigation, vol.120, issue.1, pp.331-342, 2010. ,
DOI : 10.1172/JCI38702DS1
RANK Signaling Is Not Required for TNF??-Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNF??-Mediated Inflammatory Arthritis, Journal of Bone and Mineral Research, vol.43, issue.2, pp.207-213, 2004. ,
DOI : 10.4049/jimmunol.164.11.5990
Systemic tumor necrosis factor ? mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor ?-transgenic mice, Arthritis & Rheumatism, vol.23, issue.1, pp.265-276, 2004. ,
DOI : 10.4049/jimmunol.165.1.49
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, pp.131561-1574, 1999. ,
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice, Nature Medicine, vol.59, issue.8, pp.940-945, 2009. ,
DOI : 10.1016/S0002-9440(10)62055-X
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis, Canadian Medical Association Journal, vol.180, issue.1, pp.32-39, 2009. ,
DOI : 10.1503/cmaj.080486
Mast cells are essential intermediaries in regulatory T-cell tolerance, Nature, vol.174, issue.7106, pp.997-1002, 2006. ,
DOI : 10.4049/jimmunol.174.4.1783
IL-17 Promotes Bone Erosion in Murine Collagen-Induced Arthritis Through Loss of the Receptor Activator of NF-??B Ligand/Osteoprotegerin Balance, The Journal of Immunology, vol.170, issue.5, pp.2655-2662, 2003. ,
DOI : 10.4049/jimmunol.170.5.2655
Reduction of interleukin???17???induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin???4, Arthritis & Rheumatism, vol.43, issue.6, pp.1300-1306, 2000. ,
DOI : 10.1002/1529-0131(200006)43:6<1300::AID-ANR12>3.0.CO;2-D
Peroxisome proliferator-activated receptor ?? controls muscle development and oxidative capability, The FASEB Journal, vol.17, issue.15, pp.2299-2301, 2003. ,
DOI : 10.1096/fj.03-0269fje
Mast Cell-Restricted, Tetramer-Forming Tryptases Induce Aggrecanolysis in Articular Cartilage by Activating Matrix Metalloproteinase-3 and -13 Zymogens, The Journal of Immunology, vol.191, issue.3, pp.1911404-1412, 1950. ,
DOI : 10.4049/jimmunol.1300856
Mast cell phagocytosis of FimH-expressing enterobacteria, The journal of Immunology, vol.152, issue.4, pp.1907-1914, 1994. ,
Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. Functions of the Peroxisome Proliferator-Activated Receptor (PPAR) alpha and beta in Skin Homeostasis, Epithelial Repair, and Morphogenesis, vol.128, issue.2, pp.370-377, 2008. ,
Activation of Peroxisome Proliferator-activated Receptor-?? Pathway Inhibits Osteoclast Differentiation, Journal of Biological Chemistry, vol.9, issue.19, pp.14388-14393, 2000. ,
DOI : 10.1038/22572
Multiple sclerosis: a complicated picture of autoimmunity, Nature Immunology, vol.96, issue.9, pp.913-919, 2007. ,
DOI : 10.1016/j.jns.2005.03.011
Human mast cell subsets - distinct functions in inflammation?, Inflammation Research, vol.49, issue.1, pp.3-7, 2000. ,
DOI : 10.1007/PL00012386
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors, Pharmacological Reviews, vol.58, issue.4, pp.726-741, 2006. ,
DOI : 10.1124/pr.58.4.5
URL : https://hal.archives-ouvertes.fr/hal-00188041
Life without white fat: a transgenic mouse Peroxisome proliferatoractivated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, Cytokine, vol.12, issue.203, pp.3168-3181, 1998. ,
Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1?-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor ?/?-dependent mechanism, Arthritis & Rheumatism, vol.64, issue.3, pp.759-769, 2005. ,
DOI : 10.1161/01.CIR.102.15.1834
URL : https://hal.archives-ouvertes.fr/hal-01715364
PPAR?? in Placental Angiogenesis, Endocrinology, vol.151, issue.10, pp.4969-4981, 2010. ,
DOI : 10.1210/en.2010-0131
Mast cells enhance T cell activation: Importance of mast cell-derived TNF, Proceedings of the National Academy of Sciences of the United States of America, pp.6467-6472, 2005. ,
DOI : 10.1084/jem.184.4.1397
Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice, The Journal of Immunology, vol.171, issue.11, pp.6173-6177, 2003. ,
DOI : 10.4049/jimmunol.171.11.6173
Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell- deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells, Journal of Experimental Medicine, vol.162, issue.3, pp.1025-1043, 1985. ,
DOI : 10.1084/jem.162.3.1025
Physiological Functions of Peroxisome Proliferator-Activated Receptor ??, Physiological Reviews, vol.268, issue.3, pp.795-858, 2014. ,
DOI : 10.1038/sj.onc.1209160
LIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS, Annual Review of Physiology, vol.67, issue.1, pp.309-333, 2005. ,
DOI : 10.1146/annurev.physiol.66.032802.154710
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment, Proceedings of the National Academy of Sciences of the United States of America, pp.14751-14756, 2010. ,
DOI : 10.1046/j.1365-2249.2001.01665.x
The mast cell in wound healing, Veterinary Dermatology, vol.12, issue.6, pp.303-313, 2001. ,
DOI : 10.1111/j.1365-3164.1997.tb00267.x
in Vascular Inflammation, International Journal of Vascular Medicine, vol.180, issue.1, pp.2012508416-2012508425, 2012. ,
DOI : 10.1136/bmj.c5333
IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel Fc??RIIB-deficient rheumatoid arthritis mouse model, Modern Rheumatology, vol.66, issue.1, pp.270-277, 2015. ,
DOI : 10.1002/art.38202
Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis, Clin Exp Rheumatol, vol.23, issue.3, pp.323-330, 2005. ,
Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients, Annals of the Rheumatic Diseases, vol.60, issue.3, pp.187-193, 2001. ,
DOI : 10.1136/ard.60.3.187
Brodalumab, an Anti???Interleukin-17???Receptor Antibody for Psoriasis, New England Journal of Medicine, vol.366, issue.13, pp.1181-1189, 2012. ,
DOI : 10.1056/NEJMoa1109017
Effect of IL-17A blockade with secukinumab in autoimmune diseases, Annals of the Rheumatic Diseases, vol.72, issue.suppl 2, pp.116-139, 2013. ,
DOI : 10.1136/annrheumdis-2012-202371
Spectrum of mast cell activation disorders. Expert review of clinical immunology, pp.729-739, 2014. ,
TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis, The American Journal of Pathology, vol.159, issue.5, pp.1689-1699, 2001. ,
DOI : 10.1016/S0002-9440(10)63016-7
Agonists of peroxisome proliferators-activated receptors (PPAR) ??, ??/?? or ?? reduce transforming growth factor (TGF)-??-induced proteoglycans' production in chondrocytes, Osteoarthritis and Cartilage, vol.15, issue.5, pp.493-505, 2007. ,
DOI : 10.1016/j.joca.2006.10.009
T cell hybridomas by human mast cells through superantigen presentation, Journal of Leukocyte Biology, vol.66, issue.1, pp.105-112, 1999. ,
DOI : 10.1002/jlb.66.1.105
Osteoclasts are essential for TNF-?????mediated joint destruction, Journal of Clinical Investigation, vol.110, issue.10, pp.1419-1427, 2002. ,
DOI : 10.1172/JCI0215582
How safe is the use of thiazolidinediones in clinical practice? Expert opinion on drug safety, pp.15-32, 2009. ,
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, pp.22-26, 2002. ,
PPAR?? Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro, Molecular Cell, vol.4, issue.4, pp.611-617, 1999. ,
DOI : 10.1016/S1097-2765(00)80211-7
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis, Bone, vol.49, issue.4, pp.880-885, 2011. ,
DOI : 10.1016/j.bone.2011.07.004
New insights into the genetics of immune responses in rheumatoid arthritis, Tissue Antigens, vol.25, issue.Suppl 7, pp.105-118, 2012. ,
DOI : 10.1002/jcc.20084
URL : https://hal.archives-ouvertes.fr/inserm-00730978
Protection of the kidney by thiazolidinediones: An assessment from bench to bedside, Kidney International, vol.70, issue.7, pp.1223-1233, 2006. ,
DOI : 10.1038/sj.ki.5001620
Murine and human mast cell progenitors, European Journal of Pharmacology, vol.778, 2015. ,
DOI : 10.1016/j.ejphar.2015.07.016
Pemphigoid diseases. Generalised bone loss in patients with early rheumatoid arthritis, pp.320-332, 2013. ,
DOI : 10.1016/s0140-6736(12)61140-4
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.9, pp.3349-3354, 2006. ,
DOI : 10.1210/jc.2005-2226
Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis, New England Journal of Medicine, vol.316, issue.26, pp.3161622-1626, 1987. ,
DOI : 10.1056/NEJM198706253162603
Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis, Osteoporosis International, vol.15, issue.Suppl 1, pp.2325-2334, 2013. ,
DOI : 10.1359/jbmr.2000.15.1.13
Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonist (Pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (Experimental and Clinical Study), Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, vol.4, issue.4, pp.1-10, 2011. ,
DOI : 10.4137/CMAMD.S5951
Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones, Journal of Bone and Mineral Research, vol.111, issue.Suppl. 2, pp.1301-1305, 1991. ,
DOI : 10.1002/jbmr.5650061206
PPAR-?? ligands modulate effects of LPS in stimulated rat synovial fibroblasts, American Journal of Physiology-Cell Physiology, vol.275, issue.1, pp.125-158, 2002. ,
DOI : 10.1002/art.1780370601
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis, Arthritis & Rheumatism, vol.3, issue.7, pp.2338-2346, 2004. ,
DOI : 10.1111/j.1476-5381.1996.tb15972.x
Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand, Nature, vol.2, issue.7344, pp.472491-494, 2011. ,
DOI : 10.1002/pro.5560020404
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis, Journal of Endocrinology, vol.183, issue.1, pp.203-216, 2004. ,
DOI : 10.1677/joe.1.05723
Cytokine production by synovial T cells in rheumatoid arthritis, Rheumatology, vol.38, issue.3, pp.202-213, 1999. ,
DOI : 10.1093/rheumatology/38.3.202
Mast Cell-Mediated Antigen Presentation Regulates CD8+ T Cell Effector Functions, Immunity, vol.31, issue.4, pp.665-676, 2009. ,
DOI : 10.1016/j.immuni.2009.08.022
The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo, Calcified Tissue International, vol.302, issue.4, pp.285-292, 2008. ,
DOI : 10.1007/s00223-008-9175-9
Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis, European Journal of Pharmacology, vol.718, issue.1-3, pp.1-357, 2013. ,
DOI : 10.1016/j.ejphar.2013.09.019
Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717, Rheumatology, vol.19, issue.9, pp.32-38, 2009. ,
DOI : 10.1161/01.ATV.19.9.2094
Mast Cell-Associated TNF Promotes Dendritic Cell Migration, The Journal of Immunology, vol.176, issue.7, pp.4102-4112, 2006. ,
DOI : 10.4049/jimmunol.176.7.4102
T cells through antigen-dependent interactions, European Journal of Immunology, vol.94, issue.7, pp.1758-1768, 2013. ,
DOI : 10.1073/pnas.0913054107
Mast cells in rheumatic disease, European Journal of Pharmacology, vol.778, 2015. ,
DOI : 10.1016/j.ejphar.2015.03.085
Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Annals of the rheumatic diseases, pp.2014-205562, 2014. ,
Thiazolidinediones Regulate Adipose Lineage Dynamics, Cell Metabolism, vol.14, issue.1, pp.116-122, 2011. ,
DOI : 10.1016/j.cmet.2011.05.012
URL : https://doi.org/10.1016/j.cmet.2011.05.012
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nature Reviews Rheumatology, vol.60, issue.10, pp.578-582, 2009. ,
DOI : 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells, The Journal of biological chemistry, vol.270, issue.47, pp.28183-28187, 1995. ,
Mast Cells, Mastocytosis, and Related Disorders, Mast Cells, Mastocytosis, and Related Disorders, pp.163-172, 2015. ,
DOI : 10.1056/NEJMra1409760
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor, Cell, issue.7, pp.791147-1156, 1994. ,
The Role of Mast Cells in the Defence against Pathogens, PLoS Pathogens, vol.65, issue.4, p.1002619, 2012. ,
DOI : 10.1371/journal.ppat.1002619.g001
Diagnostic criteria and classification of mastocytosis: a consensus proposal, Leukemia research, pp.603-625, 2001. ,
DOI : 10.1016/S0145-2126(01)00038-8
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria, European Journal of Clinical Investigation, vol.95, issue.6, pp.435-453, 2007. ,
DOI : 10.1016/S0889-8588(05)70298-7
URL : https://hal.archives-ouvertes.fr/hal-00282493
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?, Arthritis Research & Therapy, vol.64, issue.4, p.426, 2014. ,
DOI : 10.1002/art.33396
Arguments for interleukin 1 as a target in chronic arthritis, Annals of the Rheumatic Diseases, vol.59, issue.90001, pp.81-85, 2000. ,
DOI : 10.1136/ard.59.suppl_1.i81
High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis, Allergy, vol.49, issue.3, pp.431-438, 2012. ,
DOI : 10.1016/j.bone.2011.07.004
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes???a meta-analysis, Osteoporosis International, vol.8, issue.Suppl 1, pp.427-444, 2007. ,
DOI : 10.1016/S1695-4033(00)77393-0
Role of TH-17 Cells in Rheumatic and Other Autoimmune Diseases, Rheumatology : Current Research, vol.01, issue.01, p.1, 2011. ,
DOI : 10.4172/2161-1149.1000104
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Frontiers in immunology, vol.5, p.511, 2014. ,
Bone remodeling in rheumatic disease: a question of balance, Immunological Reviews, vol.47, issue.Suppl, pp.301-312, 2010. ,
DOI : 10.4049/jimmunol.170.5.2655
The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis, Rheumatology International, vol.46, issue.Suppl 2, pp.887-893, 2012. ,
DOI : 10.1093/rheumatology/kem285
Mucosal mast cells of the rat intestine: a re-evaluation of fixation and staining properties, with special reference to protein blocking and solubility of the granular glycosaminoglycan, The Histochemical Journal, vol.252, issue.6, pp.571-582, 1983. ,
DOI : 10.1177/25.9.71326
Morphologic and Functional Evidence for Release of Mast-Cell Products in Bullous Pemphigoid, New England Journal of Medicine, vol.298, issue.8, pp.417-421, 1978. ,
DOI : 10.1056/NEJM197802232980803
Minireview: Challenges and opportunities in development of PPAR agonists. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis, pp.1756-1768, 2014. ,
Transcriptional activation of adipogenesis, Current Opinion in Cell Biology, vol.11, issue.6, pp.689-694, 1999. ,
DOI : 10.1016/S0955-0674(99)00037-X
T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors ROR?? and ROR??, Immunity, vol.28, issue.1, pp.29-39, 2008. ,
DOI : 10.1016/j.immuni.2007.11.016
URL : https://doi.org/10.1016/j.immuni.2007.11.016
Revisiting the role of mast cells in autoimmunity, Autoimmunity Reviews, vol.14, issue.9, pp.751-759, 2015. ,
DOI : 10.1016/j.autrev.2015.04.008
PPARalpha in atherosclerosis and inflammation, Biochim Biophys Acta, issue.8, pp.1771972-982, 2007. ,
Rosiglitazone inhibits HMC-1 cell migration and adhesion through a peroxisome proliferator-activated receptor gamma-dependent mechanism, Iranian journal of allergy, asthma, and immunology, vol.13, issue.1, pp.11-18, 2014. ,
Osteoimmunology and the influence of proinflammatory cytokines on osteoclasts, Biochemia medica, vol.23, issue.1, pp.43-63, 2013. ,
TNF-induced structural joint damage is mediated by IL-1, Proceedings of the National Academy of Sciences of the United States of America, pp.11742-11747, 2007. ,
DOI : 10.1084/jem.187.9.1463